Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Respiratory

Investigational RSV Vaccine Gets Fast Track Status

Diana Ernst, RPh

January 15, 2020

An investigational vaccine to protect against respiratory syncytial virus infection has received Fast Track designation from the FDA.

Ebola

First Ebola Vaccine Receives FDA Approval

Diana Ernst, RPh

December 20, 2019

The FDA has approved Ervebo (Ebola Zaire vaccine, live) for the prevention of disease caused by Zaire ebolavirus in individuals ≥18 years of age.

HIV/AIDS

New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy

Diana Ernst, RPh

December 3, 2019

Theratechnologies announced the availability of Egrifta SV, a new single-vial formulation of tesamorelin for injection.

Vector-borne Illnesses

Tafenoquine Now Available for Malaria Prevention

Diana Ernst, RPh

November 27, 2019

Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.

Prevention

ACIP Updates Pneumococcal Vaccine Recommendations

Diana Ernst, RPh

November 27, 2019

The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.

Urinary Tract Infections

Cefiderocol Approved for Complicated UTI in Patients With Limited or No Alternative Treatment Options

Diana Ernst, RPh

November 21, 2019

The FDA has approved Fetroja for the treatment of complicated urinary tract infections.

GI Illness

Omeprazole/Amoxicillin/Rifabutin Combination Capsule Receives FDA Approval for H pylori Treatment

Diana Ernst, RPh

November 6, 2019

The FDA has approved omeprazole magnesium, amoxicillin and rifabutin delayed-release capsules for the treatment of H pylori infection in adults.

Prevention

Interleukin Inhibitors Linked to Increased Infection, Cancer Risk

Diana Ernst, RPh

October 28, 2019

In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.

Urinary Tract Infections

FDA Panel Votes on Novel Antibiotic for Complicated UTI

Diana Ernst, RPh

October 18, 2019

The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of approval of cefiderocol for the treatment of complicated UTIs including pyelonephritis.